Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully ...
CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to ...
Primary endpoint met with standout sustained patency rates, with major improvements demonstrated across the board compared to standard of care Enhances clinical profile of aXess, reinforcing excellent ...
Xeltis has announced successful results from its aXess EU phase 3 trial, confirming the potential of its restorative vascular access conduit for patients undergoing hemodialysis. The multicentre study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results